Therapy indicated for children aged 3 to 14 at treatment initiation
Category: News
New funding supports development of diagnostic platform
Treatment provides option for children with growth failure
Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas!
New guidance expands treatment options for eligible patients
Updated guidance from NICE expands eligibility for dapagliflozin us
The alliance combines Lumanity’s commercial and development strategy capabilities with PICI’s translational research expertise
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, through a share purchase […]
Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid medicines to […]
First non-immunosuppressive dual-action therapy approved for eligible patients